rom 1997 to 2002, she held various senior management positions at Bristol Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales, and Head of Cardiovascular Global Marketing. She began her industry career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, overseeing phase 3b and 4 clinical studies across all therapeutic areas, including oncology. Before joining Sandoz/Novartis, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P). Dr. Torley currently serves on the advisory board of the Women Business Leaders of the US Healthcare Industry Foundation.
About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx-pharm.com.
This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar and carfilzomib, These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and
Page: 1 2 3 Related medicine technology :1
|SOURCE Onyx Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 20112
. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference3
. Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference In New York4
. Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences5
. Auxilium Pharmaceuticals Announces Investor Event to Occur at 2011 ASSH Meeting on September 9, 20116
. Inovio Pharmaceuticals to Present at Investor Conferences7
. CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million8
. Elan Pharmaceuticals Presents 7th Annual Danville Concours dElegance Weekend9
. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference10
. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program11
. Cumberland Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference in Boston